Experimental Nonstimulant Effective, Fast-Acting for ADHD
The experimental nonstimulant medication viloxazine extended-release, known as SPN-812, reduced symptoms of attention-deficit/hyperactivity disorder (ADHD) as soon as 1 week after dosing and was well tolerated in a randomized, placebo-controlled phase 3 study that included more than 400 children.
Other Articles in this Edition
Comorbid ADHD, Insomnia Associated With Poorer Mental Functioning, Productivity
New study suggests ADHD- like behavior helps spur entrepreneurial activity
Infant Attention Associated With ADHD Symptoms in Early Childhood
Experimental Nonstimulant Effective, Fast-Acting for ADHD
ADHD Drug Overprescribing Raises Concerns Over Future CV Events
Kids Exposed to Cannabis In Utero Face Higher Risk of Autism
Body dysmorphic disorder and attention deficit hyperactivity disorder (ADHD)